Kasturi V - Search Results

1

Practical considerations in the clinical application of whole-exome sequencing.

Shashi V, McConkie-Rosell A, Schoch K, Kasturi V, Rehder C, Jiang YH, Goldstein DB, McDonald MT. Shashi V, et al. Among authors: kasturi v. Clin Genet. 2016 Feb;89(2):173-81. doi: 10.1111/cge.12569. Epub 2015 Mar 15. Clin Genet. 2016. PMID: 25678066

2

Menorrhagia in patients with type I glycogen storage disease.

Austin SL, El-Gharbawy AH, Kasturi VG, James A, Kishnani PS. Austin SL, et al. Obstet Gynecol. 2013 Dec;122(6):1246-54. doi: 10.1097/01.AOG.0000435451.86108.82. Obstet Gynecol. 2013. PMID: 24201678

3

Pregnancy Outcomes in Late Onset Pompe Disease.

Goker-Alpan O, Kasturi VG, Sohi MK, Limgala RP, Austin SL, Jennelle T, Banikazemi M, Kishnani PS. Goker-Alpan O, et al. Life (Basel). 2020 Sep 11;10(9):194. doi: 10.3390/life10090194. Life (Basel). 2020. PMID: 32932790 Free PMC article.

4

COVID-19 among Physically Active and Physically Inactive Individuals.

Kalpana M, Katta R, Madhusudhan U, Gaur A, Ganji V, Taranikanti M, Nitin J, Kasturi VK. Kalpana M, et al. Among authors: kasturi vk. Maedica (Bucur). 2024 Sep;19(3):594-599. doi: 10.26574/maedica.2024.19.3.594. Maedica (Bucur). 2024. PMID: 39553359 Free PMC article.

5

Estimated cost of VEGFR TKI associated adverse events in metastatic renal cell carcinoma patients.

Yorio JT, Asnis-Alibozek AG, Kasturi V, Hutson TE. Yorio JT, et al. Among authors: kasturi v. BMC Health Serv Res. 2024 Oct 25;24(1):1283. doi: 10.1186/s12913-024-11587-8. BMC Health Serv Res. 2024. PMID: 39456060 Free PMC article.

6

Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial.

Beckermann KE, Asnis-Alibozek AG, Atkins MB, Escudier B, Hutson TE, Kasturi V, McDermott DF, Pal SK, Porta C, Rini BI, Verzoni E. Beckermann KE, et al. Among authors: kasturi v. Oncologist. 2024 Mar 4;29(3):254-262. doi: 10.1093/oncolo/oyad348. Oncologist. 2024. PMID: 38262444 Free PMC article.

7

Activity of Tivozanib in Non-clear Cell Renal Cell Carcinoma: Subgroup Analysis From a Phase II Randomized Discontinuation Trial.

Barata PC, Chehrazi-Raffle A, Allman KD, Asnis-Alibozek A, Kasturi V, Pal SK. Barata PC, et al. Among authors: kasturi v. Oncologist. 2023 Oct 3;28(10):894-900. doi: 10.1093/oncolo/oyad132. Oncologist. 2023. PMID: 37315114 Free PMC article. Clinical Trial.

8

A multicenter, phase Ib/II, open-label study of tivozanib with durvalumab in advanced hepatocellular carcinoma (DEDUCTIVE).

Mahmood S, Li D, Lee A, Rowe J, Beg M, Kasturi V, Iyer R, Abrams T, Dayyani F. Mahmood S, et al. Among authors: kasturi v. Future Oncol. 2022 Dec;18(40):4465-4471. doi: 10.2217/fon-2022-0844. Epub 2023 Mar 13. Future Oncol. 2022. PMID: 36912078

9

Tivozanib in Patients with Advanced Renal Cell Carcinoma Previously Treated With Axitinib: Subgroup Analysis from TIVO-3.

Meza L, McDermott DF, Escudier B, Hutson TE, Porta C, Verzoni E, Atkins MB, Kasturi V, Pal SK, Rini B. Meza L, et al. Among authors: kasturi v. Oncologist. 2023 Mar 17;28(3):e167-e170. doi: 10.1093/oncolo/oyac255. Oncologist. 2023. PMID: 36576430 Free PMC article. Clinical Trial.

10

Temporal Characteristics of Adverse Events of Tivozanib and Sorafenib in Previously Treated Kidney Cancer.

Zengin ZB, Pal SK, McDermott DF, Escudier B, Hutson TE, Porta C, Verzoni E, Atkins MB, Kasturi V, Rini B. Zengin ZB, et al. Among authors: kasturi v. Clin Genitourin Cancer. 2022 Dec;20(6):553-557. doi: 10.1016/j.clgc.2022.08.005. Epub 2022 Aug 23. Clin Genitourin Cancer. 2022. PMID: 36096984 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

24 results

Search Page

Filters